The UK’s life sciences sector is standing on the brink of an abyss, pushed to the edge by a toxic mix of policy failures and government inaction. A growing chorus of experts is warning that without an immediate and powerful intervention to pull it back, the entire industry risks falling into an irreversible decline.
The proximity to the edge is demonstrated by a series of high-stakes departures. MSD took a decisive step back by canceling its £1 billion research facility. Eli Lilly has also retreated from the brink, pausing its investment, while Sanofi is actively moving away, slashing its UK trial programs and freezing future capital commitments.
The push came from a set of long-standing, deeply entrenched problems within the UK’s political and healthcare systems. An uncompetitive drug pricing model, chronic underfunding for new medicines, and a uniquely burdensome clawback tax created the unstable ground on which the sector now stands. Internal government conflict has prevented any rescue attempt.
The UK’s world-class universities provide a strong anchor point, but it will take more than that to pull the sector to safety. A rescue mission of massive proportions is needed, led by a government willing to make the swift, decisive, and radical policy changes required. The alternative is to stand by and watch one of the UK’s greatest assets go over the edge.